Moderna

In over 10 years since its inception, Moderna (NASDAQ:MRNA) has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio and integrated manufacturing facilities that allow for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna’s capabilities have come together to allow the authorized use and approval of one of the earliest and most effective vaccines against the COVID pandemic.

Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past eight years. To learn more, visit .

Moderna Continues To Expect 2023 Covid-19 Sales Of $6B-$8B, Dependent On U.S. Vaccination Rates

/ / Health Care /

Moderna Continues To Expect 2023 Covid-19 Sales Of $6B-$8B, Dependent On U.S. Vaccination Rates. While the 2023 cost of sales remains elevated, the company is currently resizing its manufacturing footprint and supply base to accelerate gross margin expansion towards its longer-term target of 75-80%.

Moderna Continues To Expect 2023 Covid-19 Sales Of $6B-$8B, Dependent On U.S. Vaccination Rates Read Post »

Morgan Stanley lowered Moderna (NASDAQ:MRNA) price target to $185 from $205

/ / Health Care / ,

Morgan Stanley said in a research note that it lowered its Moderna (NASDAQ:MRNA) price target from $205 to $185 due to increased fees and capital expenditures, while maintaining a “hold” rating. The bank noted that Moderna’s fourth-quarter results were generally in line with expectations. The higher-than-expected guidance of 35%-40% for the cost of main business in 2023 is the most concerned downside factor in the bank’s forecast. Morgan Stanley added that advance filings for personalized cancer vaccines (PCV), flu 2024 and respiratory syncytial virus (RSV) vaccines, as well as a stronger U.S. commercial coronavirus market, are potential short-term upside drivers.

Morgan Stanley lowered Moderna (NASDAQ:MRNA) price target to $185 from $205 Read Post »

Moderna(NASDAQ:MRNA) Q4 2022 revenues of $5.084 billion,down 29.4% year-over-year

/ / Health Care /

February 23, 2023— Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today reported financial results and provided business updates for the fourth quarter and fiscal year 2022. Moderna(NASDAQ:MRNA)  reported Q4 earnings of $3.61 per diluted share, Analysts polled by Capital IQ expected $4.75. Moderna(NASDAQ:MRNA)  Revenue for the quarter ended Dec. 31 was $4.86 billion, Analysts surveyed by Capital IQ expected $5.02 billion. Fourth quarter 2022 revenues of $5.1 billion; GAAP net income of $1.5 billion and GAAP diluted EPS of $3.61。 Full-year 2022 revenues of $19.3 billion; GAAP net income of $8.4 billion and GAAP diluted EPS of $20.12。 Cash used for repurchases of common stock was $3.3 billion for the full year 2022. Business outlook: The Company expects product sales in the first half of 2023 of approximately $2.0 billion. Research & Development (R&D) and Selling, General & Administrative (SG&A) Expenses: Full-year expenses

Moderna(NASDAQ:MRNA) Q4 2022 revenues of $5.084 billion,down 29.4% year-over-year Read Post »

Scroll to Top